Although hypodiploid acute lymphoblastic leukemia is the most recurrent leukemia in Li–Fraumeni patients, neoplasms of myeloid origin, including MDS and AML, are also frequent, typically developing as a therapy-related complication after the treatment of primary cancer, whereas the frequency of germline TP53 variants in de novo AML was reported at only 1.1% [45,46]. The gene discussed is TP53; the disease is acute myeloid leukemia.